Medicus Pharma’s (MDCX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a report released on Monday morning,Benzinga reports. The brokerage currently has a $27.00 target price on the stock.

A number of other research analysts have also recently issued reports on the company. Zacks Research raised Medicus Pharma to a “hold” rating in a research note on Monday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a report on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Medicus Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $23.50.

Medicus Pharma Stock Down 6.1%

Shares of MDCX stock opened at $1.69 on Monday. The firm has a market cap of $37.23 million and a price-to-earnings ratio of -0.79. Medicus Pharma has a 12 month low of $1.68 and a 12 month high of $8.94. The stock has a 50-day moving average price of $2.21 and a 200 day moving average price of $2.43.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.27). Sell-side analysts predict that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Private Advisor Group LLC grew its holdings in shares of Medicus Pharma by 3.8% during the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock worth $351,000 after buying an additional 5,500 shares in the last quarter. Osaic Holdings Inc. boosted its position in Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after acquiring an additional 9,000 shares during the last quarter. Jane Street Group LLC acquired a new position in Medicus Pharma during the 2nd quarter worth approximately $41,000. Brave Asset Management Inc. bought a new position in shares of Medicus Pharma during the 3rd quarter worth approximately $46,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Medicus Pharma in the third quarter valued at approximately $59,000.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.